Advertisement

Topics

BMS buys start-up IFM for $300mm up front plus over $2bn in earn-outs

15:41 EDT 7 Aug 2017 | Elsevier Business Intelligence

Bristol-Myers Squibb Co. paid $300mm up front for IFM Therapeutics, a private start-up aiming to treat diseases by targeting ...

Original Article: BMS buys start-up IFM for $300mm up front plus over $2bn in earn-outs

NEXT ARTICLE

More From BioPortfolio on "BMS buys start-up IFM for $300mm up front plus over $2bn in earn-outs"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...